2 March 2015
RIGHTMOVE PLC
DIRECTOR/PDMR SHAREHOLDING
Rightmove plc (the "Company"), has received the following notifications today
from Nick McKittrick, Chief Executive Officer, Peter Brooks-Johnson, Chief
Operating Officer and Robyn Perriss, Finance Director:
Nick McKittrick has confirmed that he has today been awarded Nil cost deferred
shares over 7,546 ordinary shares of 1p each following achievement of the 2014
bonus targets. The deferred shares are exercisable for 12 months from 2 March
2017. Nick McKittrick has also been awarded Nil cost performance shares over
29,321 ordinary shares of 1p each. The performance shares are exercisable for a
period of 2 years from 2 March 2018 subject to performance criteria being met.
Following this transaction, the beneficial shareholding of Nick McKittrick is
141,027 ordinary shares representing 0.15% of the ordinary shares in issue
(excluding shares held in treasury). Nick McKittrick also holds executive and
Sharesave options over 395,070 ordinary shares, deferred share awards over
31,954 ordinary shares and 180,210 performance shares.
Peter Brooks-Johnson has confirmed that he has today been awarded Nil cost
deferred shares over 6,320 ordinary shares of 1p each following achievement of
the 2014 bonus targets. The deferred shares are exercisable for 12 months from
2 March 2017. Peter Brooks-Johnson has also been awarded Nil cost performance
shares over 24,556 ordinary shares of 1p each. The performance shares are
exercisable for a period of 2 years from 2 March 2018 subject to performance
criteria being met.
Following this transaction, the beneficial shareholding of Peter Brooks-Johnson
is 22,483 ordinary shares representing 0.02% of the ordinary shares in issue
(excluding shares held in treasury). Peter Brooks-Johnson also holds executive
and Sharesave options over 270,428 ordinary shares, deferred share awards over
24,927 ordinary shares and 123,538 performance shares.
Robyn Perriss has confirmed that she has today been awarded Nil cost deferred
shares over 4,999 ordinary shares of 1p each following achievement of the 2014
bonus targets. The deferred shares are exercisable for 12 months from 2 March
2017. Robyn Perriss has also been awarded Nil cost performance shares over
19,425 ordinary shares of 1p each. The performance shares are exercisable for a
period of 2 years from 2 March 2018 subject to performance criteria being met.
Following this transaction, the beneficial shareholding of Robyn Perriss is
1,411 ordinary shares representing 0.001% of the ordinary shares in issue
(excluding shares held in treasury). Robyn Perriss also holds executive and
Sharesave options over 1,822 ordinary shares, deferred shares awards over
11,524 ordinary shares and 65,298 performance shares.
All the above share awards were made following a meeting of the Remuneration
Committee on 2 March 2015.
This announcement is made under the UKLA's Disclosure and Transparency Rule
3.1.4R.
Ends
Name and contact number for queries:
Jenny Warburton 0207 087 0739
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.